ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Gilead: Majority Of Certain Hep C Genotype 1 Patients Saw Viral Relapse

DOW JONES NEWSWIRES Gilead Sciences Inc. (GILD) said the majority of certain hepatitis C genotype 1 patients it treated with its GS-7977 drug plus ribavirin had viral relapse within four weeks of completing 12 weeks of treatment, potentially putting into question the efficacy of the drug in some patients. Shares were down 8.8% premarket at $50. As of Thursday's close, the stock has risen 34% since the start of 2012. The biopharmaceutical last month completed its purchase of Pharmasset Inc. for more than $11 billion, in a deal expected to accelerate its hepatitis C drug pipeline. It said earlier this month that its GS-7977 drug--which it acquired in the deal--along with the older drug ribavirin, made hepatitis C undetectable after four weeks of treatment in all 10 patients with genotypes 2 and 3 treated. The trial was also the first to successfully eliminate interferon from the drug treatment. Interferon is a highly toxic, older hepatitis C drug with major side effects, and market watchers are keenly focused on drug developers finding ways to strip out that treatment from future hepatitis C regimens. But, among eight genotype 1 patients treated, six experienced viral relapse. Two patients didn't, but they have only reached the two-week post-treatment time point. Those patients had a prior "null" response to an interferon-containing regimen. "These data answer an important question about the use of GS-7977 and ribavirin for the treatment of genotype 1 null responder patients, suggesting that additional direct acting antivirals may be necessary to effectively treat this patient population," said Chief Scientific Officer Norbert Bischofberger. "We will continue to explore a number of therapeutic approaches to address this significant unmet medical need, including combinations with other oral antivirals." Results from ongoing studies, including those involving genotype 1 treatment-native patients, will be released in the coming months. Gilead earlier this month said its fourth-quarter earnings rose as the company's product sales continued to rise and it no longer booked deep reductions in royalties. -By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
02/06/201613:22:00Gilead Sciences gibt Finanzergebnisse für viertes Quartal und...
02/05/201622:29:00Gilead Sciences annonce ses résultats financiers pour le quatrième t...
02/05/201605:30:00Gilead Sciences comunica i risultati finanziari registrati nel...
02/03/201617:46:13Statement of Changes in Beneficial Ownership (4)
02/03/201617:45:43Statement of Changes in Beneficial Ownership (4)
02/03/201617:45:19Statement of Changes in Beneficial Ownership (4)
02/03/201617:44:50Statement of Changes in Beneficial Ownership (4)
02/03/201617:43:57Statement of Changes in Beneficial Ownership (4)
02/03/201617:42:10Statement of Changes in Beneficial Ownership (4)
02/03/201616:13:00Merck Posts Lower Revenue and Profit -- 2nd Update
02/03/201616:09:00Correction to Merck Earnings Story
02/03/201616:07:40Current Report Filing (8-k)
02/03/201613:08:00Merck Revenue and Profit Falls -- Update
02/03/201608:30:00Merck Revenue and Profit Falls
02/03/201607:44:00Gilead Sciences annonce la déclaration du dividende en espèces d...
02/03/201603:24:00Gilead Sciences kündigt Bardividende für 1. Quartal und Erhöhungen de...
02/02/201622:28:00Gilead Sciences annuncia la dichiarazione del dividendo in contanti...
02/02/201618:29:00Gilead Hepatitis C Drugs Beat Sales Views -- Update
02/02/201617:30:00Gilead Hepatitis C Drugs Beat Sales Views
02/02/201617:11:00Gilead Hepatitis C Drugs Beat Sales Views

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad